Effect of Magnesium Oxide Supplementation on Nocturnal Leg Cramps: A Randomized Clinical Trial
Roguin Maor N, Alperin M, Shturman E, Khairaldeen H, Friedman M, Karkabi K, Milman U
JAMA internal medicine · 22 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-02-27 · JAMA Intern Med · vol. 177 · número 5 · pág. 617
- Editorial
- American Medical Association
- Citado
- 38 citas · más que el 90% de estudios similares · 2.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Diagnosis and Treatment of Venous Diseases · Dietary Effects on Health · Wound Healing and Treatments
- Palabras clave
- Medicine, Bedtime, Placebo, Volunteer, Randomized controlled trial, Magnesium, Regimen, Clinical trial, Internal medicine, Physical therapy, Anesthesia
- MeSH
- humans, sleep-wake transition disorders, magnesium oxide, treatment outcome, double-blind method, sleep, quality of life, dietary supplements, aged, middle aged, israel, female, male, early termination of clinical trials, surveys and questionnaires
7 autores
- Noga Roguin Maor🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Mordechai Alperin🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Elena Shturman🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Hassan Khairaldeen🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Moran Friedman🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Khaled Karkabi🇮🇱Technion – Israel Institute of Technology; Clalit Health Services
- Uzi Milman🇮🇱 · autor de correspondenciaTechnion – Israel Institute of Technology; Clalit Health Services
Resumen
El texto original del estudio, en el idioma en que se publicó.
Importance
Magnesium supplements are widely marketed for prophylaxis of nocturnal leg cramps (NLC) despite no evidence of significant benefit.
Objective
To determine whether magnesium oxide is better than placebo for NLC prophylaxis.
Design, setting, and participants
A randomized, double-blind, placebo-controlled clinical trial of 2 weeks eligibility screening followed by 4 weeks of treatment was conducted in northern Israel, from February to October 2013. An intention-to-treat data analysis was performed from March 22, 2014, to April 17, 2016. We used a volunteer sample of community-dwelling individuals experiencing NLC, 21 years or older, with 4 or more documented episodes of NLC during 2 weeks of screening.
Interventions
Capsules containing either magnesium oxide or a similar-looking placebo to be taken orally, once daily at bedtime for a period of 4 weeks.
Main outcomes and measures
The primary outcome was the difference in the mean number of NLC per week between the screening and treatment phases. Secondary outcomes included severity and duration of NLC, quality of life, and quality of sleep.
Results
Of the 166 volunteers, 72 (43%) were excluded, of whom 15 declined to participate and 57 did not meet the inclusion criteria. Of the 94 individuals (39% male; mean [SD] age, 64.9 [11.1] years) randomly assigned to magnesium oxide (48) or placebo (46), 6 did not complete the study protocol (3 in each group). Mean (SD) change of NLC was -3.41 (4.05) (from 7.84 [5.68] to 4.44 [5.66]) and -3.03 (4.53) (from 8.51 [5.20] to 5.48 [4.93]) per week in the magnesium oxide and placebo groups, respectively, a difference between groups of 0.38 (0.48) NLC per week (P = .67 in an intention-to-treat analysis). There were no between-group differences in the severity and duration of NLC, quality of life, or quality of sleep.
Conclusions and relevance
Oral magnesium oxide was not superior to placebo for older adults experiencing NLC. The decrease in the mean number of NLC per week, from the screening to the treatment phase in both groups, is probably a placebo effect that may explain the wide use of magnesium for NLC.
Trial registration
clinicaltrials.gov Identifier: NCT01709968.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.